Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
Stock Snapshot
As of today, Biogen(BIIB) shares are valued at $195.50. The company's market cap stands at 28.69B, with a P/E ratio of 21.75.
As of 2026-02-12, Biogen(BIIB) stock has fluctuated between $189.00 and $196.40. The current price stands at $195.50, placing the stock +3.4% above today's low and -0.5% off the high.
The Biogen(BIIB)'s current trading volume is 1.66M, compared to an average daily volume of 1.85M.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $202.41 at its peak.
During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $202.41 at its peak.
BIIB News
Biogen (BIIB) is back in focus after its fourth quarter results topped Wall Street expectations, with newer drugs such as Leqembi and other recent launches help...
Biogen ( (BIIB) ) just unveiled an announcement. On February 11, 2026, Biogen announced that Caroline Dorsa, Chair of the company’s Board of Directors, will no...
Biogen (BIIB) announced that the board of directors has elected Maria Freire as chair of the board of directors, effective immediately following the company’s 2...
Analyst ratings
54%
of 37 ratingsMore BIIB News
Wedbush analyst Laura Chico raised the firm’s price target on Biogen (BIIB) to $187 from $178 and keeps a Neutral rating on the shares. The firm notes the compa...
Biogen (NasdaqGS:BIIB) reports strong commercial performance for Alzheimer’s treatment Leqembi, reflected in collaboration revenues and in market sales. The US...
Biogen Inc (NASDAQ:BIIB) reported better-than-expected fourth-quarter results, prompting analysts to share insights on the company’s trajectory. Wedbush analyst...
Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings. The company posted quarterly adjusted EPS of $1.99, beating the conse...
BMO Capital raised the firm’s price target on Biogen (BIIB) to $196 from $165 and keeps a Market Perform rating on the shares after its Q4 earnings beat. Revenu...
Eisai (ESAIY) and Biogen (BIIB) announced that the Biologics License Application, BLA, for the subcutaneous formulation of “Leqembi,” an anti-amyloid beta proto...
UBS analyst Michael Yee maintained a Hold rating on Biogen on February 6 and set a price target of $185.00. Valentine's Day Sale - 70% Off Unlock hedge fund-lev...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.